Uploaded June 2026 | Updated September 2026, 3 weeks ago
New Phase 3 data just published in The Lancet — retatrutide (Eli Lilly's triple GIP/GLP-1/glucagon agonist) showed remarkable results for type 2 diabetes in the TRANSCEND-T2D-1 trial, including nearly 17% body weight loss (36.6 lbs) at just 40 weeks, with no plateau in sight. In this video I break down exactly what the trial found, how it compares to tirzepatide (Mounjaro) in the SURPASS-1 trial, and what the ADA's 2026 Standards of Care update means for the future of T2D treatment.
A few weeks ago I covered the TRIUMPH-1 obesity trial results for retatrutide — link below. Today we're going deeper on the TYPE 2 DIABETES side of the story.
WHAT YOU'LL LEARN:
• What makes retatrutide different — the triple mechanism (GLP-1 + GIP + Glucagon) explained simply
• TRANSCEND-T2D-1 trial design and who was studied
• A1C reduction results vs tirzepatide (SURPASS-1) — side by side
• Weight loss results — why retatrutide outperformed tirzepatide by ~75% at 40 weeks
• Cardiometabolic benefits: triglycerides, cholesterol, blood pressure
• Side effects and discontinuation rates
• What comes next — TRANSCEND-T2D-4 (vs semaglutide), FDA approval outlook
LINKS:
🔗 My TRIUMPH-1 obesity results breakdown:
youtu.be/LjvzHUtW-mQ
🔗 TRANSCEND-T2D-1 full paper (The Lancet): thelancet.com/journals/lancet/article/PIIS0140-6736(26)00967-0/abstract
=======================================================
Affiliate Links (I earn commission for qualifying purchases)
Join Fridays (GLP-1/TRT) Use Code RMZ: joinfridays.com/?via=RMZ
Gruns: grns.sjv.io/AgoLV7
========================================================
Social Links
tiktok.com/@roundmoundofzepbound
instagram.com/roundmoundofzepbound
========================================================
DISCLAIMER: No information provided here is to be construed as medical advice. Always consult with a licensed medical provider for medical advice.
#glp1 #zepbound #mounjaro #weightloss #weightlossjourney #glp #tirzepatide #semaglutide #wegovy #ozempic #menshealth #beforeandafter #beforeandafterweightloss
New Phase 3 data just published in The Lancet — retatrutide (Eli Lilly's triple GIP/GLP-1/glucagon agonist) showed remarkable results for type 2 diabetes in the TRANSCEND-T2D-1 trial, including nearly 17% body weight loss (36.6 lbs) at just 40 weeks, with no plateau in sight. In this video I break down exactly what the trial found, how it compares to tirzepatide (Mounjaro) in the SURPASS-1 trial, and what the ADA's 2026 Standards of Care update means for the future of T2D treatment.
A few weeks ago I covered the TRIUMPH-1 obesity trial results for retatrutide — link below. Today we're going deeper on the TYPE 2 DIABETES side of the story.
WHAT YOU'LL LEARN:
• What makes retatrutide different — the triple mechanism (GLP-1 + GIP + Glucagon) explained simply
• TRANSCEND-T2D-1 trial design and who was studied
• A1C reduction results vs tirzepatide (SURPASS-1) — side by side
• Weight loss results — why retatrutide outperformed tirzepatide by ~75% at 40 weeks
• Cardiometabolic benefits: triglycerides, cholesterol, blood pressure
• Side effects and discontinuation rates
• What comes next — TRANSCEND-T2D-4 (vs semaglutide), FDA approval outlook
LINKS:
🔗 My TRIUMPH-1 obesity results breakdown:
youtu.be/LjvzHUtW-mQ
🔗 TRANSCEND-T2D-1 full paper (The Lancet): thelancet.com/journals/lancet/article/PIIS0140-6736(26)00967-0/abstract
=======================================================
Affiliate Links (I earn commission for qualifying purchases)
Join Fridays (GLP-1/TRT) Use Code RMZ: joinfridays.com/?via=RMZ
Gruns: grns.sjv.io/AgoLV7
========================================================
Social Links
tiktok.com/@roundmoundofzepbound
instagram.com/roundmoundofzepbound
========================================================
DISCLAIMER: No information provided here is to be construed as medical advice. Always consult with a licensed medical provider for medical advice.
#glp1 #zepbound #mounjaro #weightloss #weightlossjourney #glp #tirzepatide #semaglutide #wegovy #ozempic #menshealth #beforeandafter #beforeandafterweightloss
